Multitarget Immunomodulation by <i>Syzygium aromaticum</i> Bud: Suppression of TLR-4/Nf-kb and Enhancement of IL-10 Axis in Diabetic Lymphocytes
Background: Chronic low-grade inflammation is a key contributor to the progression of Type 2 Diabetes Mellitus (T2DM) and is driven by elevated pro-inflammatory cytokines and dysregulated immune signalling. Natural compounds with immunomodulatory potential are promising therapeutics for restoring immune homeostasis. Aim: This study investigated the immunomodulatory effects of the aqueous fraction of Syzygium aromaticum (clove) buds on lymphocytes isolated from patients with diabetes and healthy donors. Methods: Lymphocytes were cultured ex vivo in the presence of 100 ?g/mL aqueous extract for 24 h. The gene expression of cytokines and immune markers was assessed using quantitative Real-Time PCR (qRT-PCR). Protein levels of key cytokines (IL-6, TNF-?, IL-10, and IFN-?) were measured using ELISA. Results: Lymphocytes from diabetic patients exhibited elevated expression and secretion of pro-inflammatory markers including TNF-?, IL-6, IFN-?, and IL-1?. Treatment with the extract significantly downregulated these markers, while also reducing NF-?B, TLR4, and iNOS expression. The treatment enhanced the anti-inflammatory cytokines IL-10 and IL-4. In healthy lymphocytes, the extract safely promoted IL-10 production without triggering immune over activation. Conclusion: These findings support the potential of the aqueous fraction of S. aromaticum buds as a safe and effective adjunct to diabetes immunotherapy for restoring immune balance. Major Findings: The aqueous fraction of S. aromaticum buds exerted targeted immunomodulatory effects, reducing pro-inflammatory signalling and enhancing immune regulation in diabetic lymphocytes.